Sachin Mamidwar, M.D.

AIMBE College of Fellows Class of 2012
For significant contributions for the development of Bone Graft Materials and its introduction to the market.

Orthogen LLC Announces Dr. Sachin Mamidwar as New CEO of Company

Via SBWire | October 29, 2013

Orthogen LLC, a leading provider of bone graft material for dental applications, is pleased to announce the appointment of Dr. Sachin Mamidwar as new CEO of the company. Previous CEO and Chairman of the Board of Orthogen LLC, Dr. Harold Alexander said, “The opinion of the owners was unanimously positive. It is with great pleasure that we therefore name Dr. Sachin Mamidwar the new CEO of the corporation. He has played a critical leadership role in the development and commercialization of our nanotechnology based bone graft material, NanoGen and in obtaining ISO certification for the company. I am sure he will continue to move the company forward providing unique and quality products to the dental and medical communities.” “I am excited to take this new responsibility”, said Dr. Sachin Mamidwar. “Since Orthogen, LLC’s formation in 2007, we have successfully pursued Small Business Innovation Research grant to develop the nanotechnology based bone graft material, NanoGen. This is the only nanotechnology-based material approved by US FDA for dental bone grafting purposes. Clinical studies have demonstrated outstanding results using NanoGen in extraction sockets, infrabony defects, class II furcation defects and sinus augmentation cases. It is now time to capitalize on these outstanding results to increase market penetration for this bone graft material. And I look forward to work on this challenge”, continued Dr. Mamidwar. He also said he would like to introduce Orthogen, LLC’s products in orthopedics and discussions about the same are ongoing with major orthopedic distributors in the US.

Bone Grafting — Is There Another Way?

Via Medical Device and Diagnostic Industry | May 7, 2013

When a bone graft is performed, surgeons use allografts from dead bodies, autografts from the patient himself, and occasionally from the bone of an animal, or xenografts. Each of these pose a certain amount of risk, which is why many companies are looking for ways around it, producing new materials in a laboratory setting that could potentially replace the procedure.

Ceramics, demineralized bone matrix, bone morphogentic protein and graft composites have all been used for grafting. However, there are several companies that are thinking beyond the traditional grafting system.

Sachin Mamidwar, general manager for Orthogen, has developed a calcium sulfate bone graft system that can be used as either the graft system alone or with another grafting system. NanoGen is different in that it stimulates bone growth, but is scheduled to dissolve away in 12 weeks. This process means that there is no other surgical procedure other than implantation, and the material is completely broken down in the system. “We are not looking to replace the bone,” he said. “What we are looking at is to regenerate the bone.”

Mamidwar said that calcium sulfate has been used as a bone grafting material for 100 years, calling it, “the oldest biomaterial.” However, the company’s nanotechnology makes it longer lasting in the body to stimulate the bone growth required in order to make a procedure successful.